Pillstats
Rx only · Kit

Octreotide Acetate

Brands: Sandostatin Lar Depot

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US6 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCH01CB02
RxCUI (US)7617
US makers2 labelers
Packages6
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 3 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$1443.22$2886.43$4329.65$5772.87Dec 2025Apr 2026Jul 2026
$5019.887
Latest avg · Jul 8, 2026
+4%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

8571.7K2.6K3.4K2025 Q12025 Q22025 Q32025 Q42026 Q1
1.8K
Rx · 2026 Q1
2.0K
Units dispensed
-37%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Mylan Institutional LLCunknown3SUPPLYING
Novartis Pharmaceuticals Corporationunknown3SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.